Search studies
22 studies found
AETIONOMY
dc9ac40c-147a-11eb-b51f-8c8590c45a21
Study phase: recruitment. For more details, see http://www.aetionomy.eu/content/dam/scai/AETIONOMY/Dokumente/Aetionomy_Newsletter4_web.pdf
APPROACH longitudinal study
df77529e-c79d-11ec-9b1d-acde48001122
EPAD
dc9ad7c6-147a-11eb-b51f-8c8590c45a21
Observational Study. More details available at http://datacat.uni.lu/additional_files/EPAD_Study_Protocol_Description.htm
IMIDIA Cohort 1
a7a855a2-54b7-11eb-9562-acde48001122
Identification of tissue-specific and common methyla...
c7515074-b34a-11eb-9969-acde48001122
Understanding the influence of genetic variants on DNA methylation is fundamental for the interpretation of epigenomic data in the context of disease. The dataset developed in this project provides matched genotyping and DNA methylation data in four tissues (ileum, rectum, T-cells, B-cells) from healthy individuals. Using this data, we demonstrate the discrimination of common from cell-type-specific methQTLs. Our analysis demonstrates that a systematic analysis of methQTLs provides important ...
OncoTrack
dc9c42f0-147a-11eb-b51f-8c8590c45a21
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...
OncoTrack study
ELU-4-24D114-1
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...
